CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal

Positive
AI Analysis

Summary

Ipsen is acquiring Swiss biotech Memo Therapeutics in a potential $800M deal to gain an experimental medicine in late-stage testing for a virus affecting kidney transplant patients.

Importance:7/10
Sentiment:
0.60
M&Aacquisitionlate-stage developmentkidney transplant
Related Companies

Read the original article

Published by BioPharma Dive on July 1, 2026 1:51 PM

Read Original